IngentaConnect The Current Treatment of Ductal Carcinoma in Situ

Author: Schwartz, Gordon F.¹

Source: The Breast Journal, Volume 7, Number 5, September/October 2001 , pp. 308-310(3)

Abstract:

A consensus conference was held in April, 1999, to help sift through the maze of controversy surrounding the treatment of mammographically detected ductal carcinoma in situ (DCIS). Members of the panel included approximately 30 DCIS experts, who addressed issues relating diagnosis, treatment, treatment of breast (and axilla), adjuvant theraphy, among others. The panel agreed that the goal of treatment for DCIS is breast conservation and attempted to divide the population of patients with DCIS into subsets who are appropriately treated by mastectomy, radiation theraphy, or by excision alone. Major criteria for breast conservation include small size of area of DCIS, clear surgical margins, and favorable biology. Neither axilliary dissection nor sentinel node biopsy is appropriate for DCIS treated by breast conservation. The role of tamoxifen is currently under study, and although approved by the FDA for “risk reduction,” its use in patients with DCIS is uncertain.

Keywords: breast neoplasms; ductal carcinoma in situ; DCIS; carcinoma in situ

Document Type: Research article

DOI: 10.1046/j.1524-4741.2001.22057.x

Affiliations: 1: Department of Surgery, Jefferson Medical College and the Breast Health Institute, Philadelphia, Pennsylvania

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.39 plus tax Refund Policy